[144] Axsome Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Notice of proposed sale of common stock by an insider. The filing reports a proposed sale of 19,220 shares of common stock through Goldman Sachs & Co. LLC with an aggregate market value of $2,305,246.80. The filer indicates the shares were originally acquired on 05/27/2016 as compensation via stock options and were exercised in a cashless exercise / same-day sale on the acquisition date. The issuer shows 49,901,487 shares outstanding and the proposed sale date is 10/06/2025. The filing also discloses three recent open-market sales by the same person in 09/2025 totaling 62,880 shares for gross proceeds of $7,105,964.54. The signer affirms they are not aware of undisclosed material adverse information and references Rule 10b5-1 procedures, though no plan adoption date is provided.

Positive

• Transparent disclosure of proposed sale amount (19,220 shares) and $2,305,246.80 aggregate value
• Brokered transaction through Goldman Sachs & Co. LLC, indicating standard market execution
• Prior open-market sales in 09/2025 are reported with gross proceeds of $7,105,964.54, showing execution history

Negative

• None.

Insights

Insider Transactions Analyst

Insider plans modest open-market sales over time; recent activity shows execution.

The filing documents a proposed sale of 19,220 shares via Goldman Sachs with a stated market value of $2.31M, and prior sales in 09/2025 totaling 62,880 shares for $7.11M. The shares were acquired as compensation in 05/2016, indicating these are not newly issued shares but insider-held shares converted by option exercise.

Key dependencies include whether a written 10b5-1 plan governs timing (no adoption date shown) and the market price at the proposed sale date 10/06/2025. Watch near-term insider sale filings and actual trade execution for any clustering that could affect perceptions of insider selling over a quarter.

Corporate Governance Specialist

Disclosure follows Rule 144 mechanics; representations on nonpublic information are included.

The filer affirms the standard Rule 144 representation that they have no material nonpublic information and references Rule 10b5-1 trading-plan considerations, although the filing leaves plan-adoption fields blank. The presence of a broker and prior executed sales demonstrates routine open-market liquidation rather than an issuance or secondary offering.

Investors may monitor subsequent Form 4/Form 144 updates to confirm settlement dates and any disclosed trading-plan dates within the next few weeks to clarify whether sales are pursuant to a prearranged plan or discretionary decisions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	19220	2305246.8	49901487	10/06/2025	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/27/2016	Acquired as compensation -- Stock Options	The Issuer			19220	05/27/2016	Compensation -- Cashless exercise / same-day sale

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Herriot Tabuteau One World Trade Center 29th Floor New York NY 10007	Common Stock	09/12/2025	27907	3319894.86
Herriot Tabuteau One World Trade Center 29th Floor New York NY 10007	Common Stock	09/15/2025	15254	1790378.76
Herriot Tabuteau One World Trade Center 29th Floor New York NY 10007	Common Stock	09/16/2025	19719	2251690.92

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Axsome (AXSM) Form 144 report?

It reports a proposed sale of 19,220 common shares through Goldman Sachs with an aggregate market value of $2,305,246.80, proposed for 10/06/2025.

When were the shares being sold originally acquired?

The shares were acquired on 05/27/2016 as compensation via stock options and were exercised via a cashless exercise / same-day sale.

Has the filer recently sold other AXSM shares?

Yes. The filer sold 62,880 shares in 09/2025 across three trades, producing gross proceeds of $7,105,964.54.

Does the filing state the filer has material nonpublic information?

No. The signer represents they do not know of any undisclosed material adverse information and references Rule 10b5-1 procedures, but no plan-adoption date is provided.

How large is the proposed sale versus shares outstanding?

The proposed 19,220 shares represent a small fraction of the 49,901,487 shares outstanding (well under 1 of outstanding shares).